Shilpa Medicare, a company in the Pharmaceuticals industry, reported revenue of ₹529 crore and net profit of ₹79 crore for the September 2026 quarter.
Shilpa Medicare (NSE: SHILPAMED) closed at ₹849.15 on 20 Nov 2026, up 138.3% over the past year. Its market capitalisation is ₹16,608 crore and it trades at 51.9 times earnings.
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.